Instructions:
Instructional text – requires you to complete the information. Remove the italics prior to finalising
the GP Letter and ensure all text is black. DO NOT SEND THIS LETTER WITHOUT PATIENT
CONSENT FOR THIS TRIAL
Optional text – requires you to choose one of the options and delete the other as applicable to
your trial.
Standard wording – not to be removed or changed without prior consultation with the CCTU
TO BE PRINTED ON HEADED PAPER
Date
Dear Doctor Name
RE: Trial Title
Patient Name and DOB
I am writing to inform you that your patient has agreed to participate in the above clinical trial
at (Local hospital name). Add a brief description of the trial design (e.g. open, uncontrolled
non-randomised trial) and the name of the IMP(s). Include the sponsor name.
The purpose of this Trial is to
BRIEFLY explain why this study is taking place and why the patient has been asked to
participate. Provide dosing information, including the frequency of dosing and the length of
patient participation. DETAIL any information regarding potential changes to the patient’s
medication/treatment or lifestyle that may be relevant for the GP.
Contraindications
Give details of possible interaction of trial IMP with other medication or procedures that the
GP needs to be aware of.
The main side effects to be aware of are detailed in the enclosed Participant Information
Sheet.
I have enclosed a copy of the Participant Information Sheet for your reference, however if
you have any queries or require further information please contact (Insert local contact
details including contact number and website if available).
In the event of an emergency please call: Insert emergency telephone number which
must match the telephone number on the PIS
Yours Sincerely
Local Contact Name
Role
Hospital
Encs: Participant Information Sheet, version (insert version number) dated (insert date)
CCTU/TPL015 V3 Approved 18/11/2019
Reviewed 18/11/2019
Page 1 of 1
IRAS ID: